Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction adenocarcinoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05170503
Study type Interventional
Source Sun Yat-sen University
Contact Hong Yang, M.D. Ph.D.
Phone +8613560405144
Email yanghong@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date December 29, 2021
Completion date January 1, 2029

See also
  Status Clinical Trial Phase
Withdrawn NCT05001360 - Study of FMT Combined With Nivolumab in Gastric Cancer N/A
Enrolling by invitation NCT04153058 - Clinical Outcomes of Robotic Versus Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III AEG N/A
Recruiting NCT04423354 - A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG N/A
Not yet recruiting NCT06461910 - Efficacy and Safety of Anti-PD-1, Thymosin, and SOX in Neoadjuvant Treatment of cStage III Gastric/GEJ Adenocarcinoma Phase 2
Completed NCT00719550 - AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer Phase 1/Phase 2